Arcutis raises 2026 sales guidance but shares fall 20.7% on the day
FROM THE WIRE · FINANCE.YAHOO.COM
Arcutis Biotherapeutics (ARQT) drew investor attention after reporting third quarter 2026 earnings, with net product revenue for ZORYVE up 45% year over year and full year sales guidance nudged higher. The reaction in Arcutis Biotherapeutics' share price has been sharp, with the…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishDespite the raised guidance, the sharp negative reaction weighs on the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Net ZORYVE product revenue rose 45% year over year in Q3.
- 02Full-year 2026 sales guidance was nudged higher.
- 03The stock fell about 20.7% on the day and 15.8% over the past week.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets